Ivermectin as a Novel Therapy in COVID-19 Treatment

Phase 2

Completed

• Conditions: COVID
• Interventions: Drug: Ivermectin

• Registration Number: NCT04403555
• Lead Sponsor: Tanta University

Brief Summary

Efficacy of Ivermectin in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Study Timeline

• Study First Submitted: 2020-05-23
• Study First Submitted QC: 2020-05-23
• Study First Posted: 2020-05-27
• Study Start: 2020-06-01
• Primary Completion: 2020-10-31
• Study Completion: 2020-12-01
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-29
• Last Update Posted: 2021-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

• All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion Criteria

• Allergy or contraindication to the drugs used in the study.
• Pregnant and lactating mothers.
• Patients with cardiac problems.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ivermectin	Ivermectin	Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days

Primary Outcome Measures

Name	Time	Method
The number of patients with mortality	1 month	Improvement of survival

Secondary Outcome Measures

Name	Time	Method
The need for mechanical ventilation	1 month	Need for mechanical ventilation
Length of hospital stay	1 month	Effect on the length of hospital stay

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt